[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354050-105":59,"doc-detail-354050-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","her3-beyond-the-canonical-paradigm-a-versatile-signaling-hub-in-oncogenesis-and-therapeutic-resistance","HER3 beyond the canonical paradigm - a versatile signaling hub in oncogenesis and therapeutic resistance","","Human epidermal growth factor receptor 3 (HER3/ErbB3) is widely viewed as a kinase-impaired EGFR-family member that drives oncogenic signaling through heterodimerization. Emerging resistance to HER-targeted treatments has intensified interest in HER3’s functions beyond its canonical paradigm. This review maps HER3’s non-canonical signaling landscape, including alternative heterodimerization partners, nuclear transcriptional co-regulatory activity, and cancer-type–dependent prognostic complexity. It integrates mechanistic evidence on metabolic reprogramming, tumor microenvironment regulation, and adaptive resistance across radiotherapy, chemotherapy, and immunotherapy, proposing a framework for next-generation HER3-targeted strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/her3-beyond-the-canonical-paradigm-a-versatile-signaling-hub-in-oncogenesis-and-therapeutic-resistance/354050/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/her3-beyond-the-canonical-paradigm-a-versatile-signaling-hub-in-oncogenesis-and-therapeutic-resistance/354050.png","ImageObject",300,407,{"name":92,"@type":93},"Angel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is HER3 considered beyond the canonical paradigm in oncogenesis?","Question",{"text":112,"@type":113},"HER3 can initiate signaling through heterodimerization, but therapy-driven resistance and emerging evidence highlight broader, non-canonical roles. The review emphasizes mechanisms that extend beyond the classical view of HER3 function.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What non-EGFR family partners does the review discuss for HER3 heterodimerization?",{"text":117,"@type":113},"The review summarizes non-EGFR heterodimerization partners including MET, FGFR, and IGF1R. It links these interactions to distinct functional outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"How does HER3 contribute to therapeutic resistance across different treatment modalities?",{"text":121,"@type":113},"The review integrates findings that tumor cells hijack HER3 to reprogram metabolism and regulate the tumor microenvironment. These non-canonical mechanisms collectively support adaptive resistance to radiotherapy, chemotherapy, and immunotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354050,1790205594,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Li et al. Journal of Translational Medicine (2026) 24:554  \n[https://doi.org/10.1186/s12967-026-07934-4](https://doi.org/10.1186/s12967-026-07934-4)  \nJournal of Translational Medicine  \nREVIEW Open Access  \nHER3 beyond the canonical paradigm: a versatile signaling hub in oncogenesisand therapeutic resistance  \nYing Li1, Zhuo Wang1, Meichen Gu1, Fuxue Huang1 and Pengyu Chang1*  \nAbstract  \nBackground Human epidermal growth factor receptor 3 (HER3/ErbB3) is classically recognized as a kinaseimpaired member of the epidermal growth factor receptor (EGFR) family, which can initiate oncogenic signaling by heterodimerizing with family members. However, the emerging drug resistance issues of HER-targeted therapies emerges have urged researchers to decipher the role of HER3 as a versatile signaling hub, which is beyond its canonical paradigm.  \nMain body This review delineated the non-canonical landscape of HER3, providing a specialized dissection of its roles which distinguished from the general overviews. We summarized the non-EGFR family heterodimerization partners for HER3 (e. g. MET, FGFR, and IGF1R) and its unique role as a transcriptional co-regulator in the nucleus, and discussed the clinical conundrum regarding its divergent prognostic roles in different cancer types. By integrating the cutting-edge findings in recent years, this review presented the pivotal role of tumor cells hijacking HER3 to achieve metabolic reprogramming and the regulation of tumor microenvironment. These non-canonical mechanisms of HER3 collectively contribute to the adaptive resistance to radiotherapy, chemotherapy, and immunotherapy.  \nConclusions By integrating current insights and analyzing unresolved paradoxes in published data, this review elaborated the versatile roles of HER3, and constructed a novel theoretical framework to lay foundation for conquering the challenges of therapeutic resistance in precision oncology by developing next-generation HER3-targeted strategies.  \nKeywords HER3, ErbB3, Non-canonical functional mechanisms, Oncogenesis, Therapeutic resistance  \n*Correspondence: Pengyu Chang [changpengyu@jlu.edu.cn](changpengyu@jlu.edu.cn)  \n1Department of Radiation Oncology and Therapy, The First Hospital of Jilin University, Changchun, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLi et al. Journal of Translational Medicine (2026) 24:554  \nBackground  \nHuman epidermal growth factor receptor 3 (HER3, also known as ErbB3) belongs to the ErbB receptor tyrosine kinase (RTK) family. It is functionally distinct from the other family members by its molecular structural features: the intracellular kinase domain itself lacks activity and cannot catalyze autophosphorylation. This structural basis decides that HER3 requires to form heterodimers with other family members (particularly HER2) to exert its function [1]. The most common ligands for HER3 are neuregul","cbCaibw5sYD2MZO4","https://ap.wps.com/l/cbCaibw5sYD2MZO4","pdf",2356870,31,"English","# Background\n# Main body\n## Non-canonical HER3 landscape and heterodimer partners\n## Nuclear co-regulatory function and prognostic paradoxes\n## Roles in metabolism, tumor microenvironment, and therapy resistance\n# Conclusions\n# Keywords","[{\"question\":\"Why is HER3 considered beyond the canonical paradigm in oncogenesis?\",\"answer\":\"HER3 can initiate signaling through heterodimerization, but therapy-driven resistance and emerging evidence highlight broader, non-canonical roles. The review emphasizes mechanisms that extend beyond the classical view of HER3 function.\"},{\"question\":\"What non-EGFR family partners does the review discuss for HER3 heterodimerization?\",\"answer\":\"The review summarizes non-EGFR heterodimerization partners including MET, FGFR, and IGF1R. It links these interactions to distinct functional outcomes.\"},{\"question\":\"How does HER3 contribute to therapeutic resistance across different treatment modalities?\",\"answer\":\"The review integrates findings that tumor cells hijack HER3 to reprogram metabolism and regulate the tumor microenvironment. These non-canonical mechanisms collectively support adaptive resistance to radiotherapy, chemotherapy, and immunotherapy.\"}]","HER3 beyond the canonical paradigm - a versatile signaling hub in oncogenesis and therapeutic resistance | PDF",1790108613,78,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3fa05de62151eb102c86876a35168a41.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef3ef3087e9913cbd153648bd26cc7fc.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16075ba2e3565cc8dd8e32d8eb7ef7fa.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/430e4ddfb3b6e6ed5b2d7e5277d1f2d5.webp",980,1306]